savolitinib Report issue

Small molecule Experimental

Active Ingredient History

NOW
  • Now
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China.   Wikipedia

Chemistry

  • SMILES: C[C@@H](c1ccc2nccn2c1)n3nnc4ncc(nc34)c5cnn(C)c5
  • InChIKey: XYDNMOZJKOGZLS-NSHDSACASA-N
  • Mol. Mass: 345.37
  • ALogP: 1.88
  • ChEMBL Molecule:
    savolitinib  
More Chemistry

Pharmacology

Organizations (22)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Adenocarcinoma (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 3)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Diffuse Intrinsic Pontine Glioma (Phase 1)

Esophageal Diseases (Phase 2)

Glioma (Phase 1)

Medulloblastoma (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Therapeutic Equivalency (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue